We are live on ! Find out more
RVMD icon

Revolution Medicines
RVMD

152 hedge funds and large institutions have $2.34B invested in Revolution Medicines in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 77 increasing their positions, 31 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

361% more call options, than puts

Call options by funds: $3.95M | Put options by funds: $857K

148% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 31

113% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 15

13% more capital invested

Capital invested by funds: $2.07B → $2.34B (+$269M)

13% more funds holding

Funds holding: 135 → 152 (+17)

4.59% more ownership

Funds ownership: 99.36% → 103.95% (+4.6%)

33% less funds holding in top 10

Funds holding in top 10: 12 → 8 (-4)

Holders
152
Holders Change
+17
Holders Change %
+12.59%
% of All Funds
2.42%
Holding in Top 10
8
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-33.33%
% of All Funds
0.13%
New
32
Increased
77
Reduced
31
Closed
15
Calls
$3.95M
Puts
$857K
Net Calls
+$3.1M
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$73.2M
2
BBA
Baker Bros. Advisors
New York
+$60.8M
3
Holocene Advisors
Holocene Advisors
New York
+$51.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$42.9M
5
BI
BVF Inc
California
+$41.9M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$45.1M
2
TGI
TRV GP III
Massachusetts
-$38.2M
3
TGI
TRV GP IV
Massachusetts
-$33.8M
4
APM
Avidity Partners Management
Texas
-$27.8M
5
CC
Casdin Capital
New York
-$17.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
151
TRV GP III
Massachusetts
– -$38.2M -1,604,130 Closed
TGI
152
TRV GP IV
Massachusetts
– -$33.8M -1,419,900 Closed
RG
153
Redmile Group
California
– -$14.9M -625,000 Closed
Point72 Asset Management
154
Point72 Asset Management
Connecticut
– -$9.13M -383,339 Closed
HF
155
HRT Financial
New York
– -$2.34M -98,186 Closed
JF
156
Jump Financial
Illinois
– -$654K -27,456 Closed
CSS
157
Cubist Systematic Strategies
Connecticut
– -$537K -22,546 Closed
Squarepoint
158
Squarepoint
New York
– -$459K -19,271 Closed
QT
159
Quantamental Technologies
New York
– -$224K -9,392 Closed
E
160
Ergoteles
New York
– -$217K -9,100 Closed
HNWAG
161
High Net Worth Advisory Group
Florida
– -$47.6K -2,000 Closed
GAG
162
Goodman Advisory Group
Massachusetts
– -$42K -1,763 Closed
BAM
163
Belpointe Asset Management
Nevada
– -$25.7K -1,078 Closed
IRC
164
Investors Research Corp
Georgia
– -$834 -35 Closed
C
165
Covestor
United Kingdom
– -$25 -1 -13%
Carson Wealth (CWM LLC)
166
Carson Wealth (CWM LLC)
Nebraska
– +$148 +6 New
SFG
167
Steward Financial Group
Texas
– +$222 +9 New
3 4 5 6
7

RVMD Hedge Fund Activity: Q1 2023 in Review

152 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q1 2023, worth a combined $2.34B — up 13% from $2.07B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new RVMD positions and 15 closed out — a net gain of 17 holders — while 77 added to existing stakes and 31 trimmed.

The largest buyer was Woodline Partners, adding an estimated $73.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $45.1M sold.

  • 152 institutional investors held Revolution Medicines (RVMD) as of Q1 2023, up from 135 in Q4 2022.
  • Funds reported $2.34B of Revolution Medicines stock for Q1 2023, up 13% quarter-over-quarter.
  • 32 funds opened new Revolution Medicines positions in Q1 2023 and 15 closed out, a net change of +17 holders.
  • The largest Revolution Medicines buyer in Q1 2023 was Woodline Partners, an estimated $73.2M added.
  • The largest Revolution Medicines seller in Q1 2023 was Cormorant Asset Management, an estimated $45.1M sold.

Based on aggregated 13F filings for Q1 2023.